We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+4.7%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$286M
AUM Growth
-$32.2M
Cap. Flow
+$12.1M
Cap. Flow %
4.24%
Top 10 Hldgs %
59.29%
Holding
46
New
14
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$12.2M
2
EPZM
Epizyme, Inc
EPZM
+$9.1M
3
AIMT
Aimmune Therapeutics
AIMT
+$8.13M
4
XLRN
Acceleron Pharma
XLRN
+$7.86M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$6.69M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$7.5M
2
KYNB
Kyntra Bio
KYNB
+$7.03M
3
TPST icon
Tempest Therapeutics
TPST
+$4.15M
4
ATYR
aTyr Pharma
ATYR
+$3.88M
5
GNVC
GenVec, Inc.
GNVC
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 76.37%
2 Miscellaneous 23.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
CALL
DELISTED
Immunogen Inc
IMGN
$2.55M 0.89%
+299,500
New +$2.53M
CYTK icon
27
CALL
Cytokinetics
CYTK
$10B
$1.76M 0.62%
250,000
-34,600
-12% -$253K
FWP
28
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.65M 0.58%
13,861
-427
-3% -$47.8K
ARRY
29
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.53M 0.54%
+520,000
New +$1.56M
AKTX
30
Akari Therapeutics
AKTX
$20.8M
$1.29M 0.45%
115
-11
-9% -$114K
ONC
31
BeOne Medicines Ltd
ONC
$41.5B
$462K 0.16%
+15,766
New +$447K
GBT
32
DELISTED
Global Blood Therapeutics, Inc.
GBT
$445K 0.16%
+28,032
New +$498K
ATYR
33
aTyr Pharma
ATYR
$53M
$295K 0.1%
5,354
-51,108
-91% -$3.88M
ONCE
34
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$257K 0.09%
+8,700
New +$274K
LRMR icon
35
CALL
Larimar Therapeutics
LRMR
$417M
$67K 0.02%
833
– –
BHC icon
36
CALL
Bausch Health
BHC
$2.36B
– –
-126,500
Closed -$12.9M
JAZZ icon
37
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
– –
-189,200
Closed -$26.6M
LRMR icon
38
Larimar Therapeutics
LRMR
$417M
– –
-30,750
Closed -$2.43M
TPST icon
39
Tempest Therapeutics
TPST
$17.5M
– –
-145
Closed -$4.15M
TVTX icon
40
CALL
Travere Therapeutics
TVTX
$6.19B
– –
-244,100
Closed -$4.71M
CALA
41
DELISTED
Calithera Biosciences, Inc
CALA
– –
-20,774
Closed -$3.18M
QLTI
42
DELISTED
QLT Inc
QLTI
– –
-100,000
Closed -$266K
NRX
43
DELISTED
NEPHROGENEX INC COM
NRX
– –
-588,235
Closed -$941K
GNVC
44
DELISTED
GenVec, Inc.
GNVC
– –
-192,091
Closed -$3.53M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2016 Portfolio in Review

As of Q1 2016, EcoR1 Capital held 46 positions worth $286M, down 10% from $318M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $12.1M of net new capital in Q1 2016, opening 14 new positions and adding to 8 existing holdings. Its largest new stake was Aimmune Therapeutics: 521,366 shares worth $7.07M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $7.5M trimmed.

  • EcoR1 Capital's largest Q1 2016 buy was Aimmune Therapeutics: 521,366 shares worth $7.07M.
  • EcoR1 Capital added most to Ironwood Pharmaceuticals in Q1 2016, an estimated $12.2M increase.
  • EcoR1 Capital's biggest Q1 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $7.5M.
  • EcoR1 Capital fully exited Tempest Therapeutics in Q1 2016, selling an estimated $4.15M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $286M portfolio in Q1 2016.
  • EcoR1 Capital opened 14 new positions and closed 9 in Q1 2016.
  • EcoR1 Capital's portfolio value fell 10% quarter-over-quarter to $286M.

Based on EcoR1 Capital's 13F filing for Q1 2016, filed 16 May 2016.